Study to assess the efficacy and safety of QVA149 in patients with COPD

Update Il y a 4 ans
Reference: EUCTR2011-004870-26

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To demonstrate non-inferiority of QVA149 110/50 µg to tiotropium 18 µg q.d. plus formoterol 12µg b.i.d. in terms of health related quality of life as assessed by St George’s Respiratory Questionnaire (SGRQ-C) after 26 weeks of treatment in moderate to severe COPD patients.


Inclusion criteria

  • Chronic Obstructive Pulmonary Disease (COPD)

Links